ISOPP CAPhO 2025 Symposium: Sponsored Symposium AstraZeneca Canada and Daiichi Sankyo Canada - Strategies for Managing ADC-Related Toxicities in Metastatic

This case-based session will explore the management of patients with metastatic breast cancer receiving antibody–drug conjugates (ADCs). The presentation will include a clinical resource designed by a multidisciplinary faculty to support nurses and pharmacists in the care of patients receiving ADCs. The presenting faculty will review the resource and discuss proactive monitoring and toxicity management strategies for trastuzumab emtansine, trastuzumab deruxtecan, and sacituzumab govitecan, demonstrating how this print tool can be employed in routine clinical practice.

Learning Objectives

• Understand key differences between the safety profiles of antibody–drug conjugates (ADCs) currently approved by Health Canada for the treatment of metastatic breast cancer, including trastuzumab emtansine, trastuzumab deruxtecan, and sacituzumab govitecan
• Integrate proactive monitoring strategies during the routine care of patients receiving ADCs • Collaborate with the multidisciplinary team for timely management of ADC-related toxicities